Search Results

Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it has completed the previously announced acquisition of Synteract, a leading full-service CRO focused on the rapidly growing, emerging biopharma segment.

Syneos Health announced on Wednesday that it has agreed to acquire Synteract, a full-service Contract Research Organization (CRO) focused on the biopharmaceutical industry.

Under Amulet’s ownership, Synteract drove organic growth, integrated several strategic acquisitions, more than doubled EBITDA and expanded its global delivery footprint

Synteract, an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, has launched the Synteract Rare Disease Institute™, which capitalizes on Synteract’s strengths and skillsets in rare and orphan diseases.

Given the enhanced strategic solutions that often result from the intersecting expertise of Synteract’s centers of development, clients will derive further benefit from the therapeutic knowledge and clinical development acumen gained from these key additions.

Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced an agreement to acquire Synteract, a full-service CRO focused on the rapidly growing emerging biopharma segment. Synteract has built a leading reputation among emerging biopharma, providing deep therapeutic expertise in oncology, rar

Synteract, an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, congratulates its Vice President, Rare and Orphan Diseases, Lisa Dilworth, for being named to the 2019 PharmaVOICE 100.

Synteract, an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, has acquired Clindata’s human health biometrics division to meet market demand for more adaptable biometrics services solutions

He joins Synteract from Chiltern, a Covance company, where he was vice president, Global Business Development Biopharma.

Synteract, an innovative contract research organization (CRO) enabling biopharma companies to bring new medicines to market, has added two experienced members to enhance its Rare and Orphan Diseases Center of Development.